The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice

被引:43
作者
Ferreira, J. C. B. [1 ]
Bacurau, A. V. [1 ]
Evangelista, F. S. [2 ]
Coelho, M. A. [1 ]
Oliveira, E. M. [1 ]
Casarini, D. E. [3 ]
Krieger, J. E. [2 ]
Brum, P. C. [1 ]
机构
[1] Univ Sao Paulo, Escola Educ Fis & Esporte, Dept Biodinam Movimento Corp Humano, BR-05508900 Sao Paulo, Brazil
[2] Univ Sao Paulo, Sch Med, Inst Heart, BR-05508900 Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Div Nephrol, Sao Paulo, Brazil
关键词
sympathetic nervous system; AT(1) receptor blocker; alpha(2a)/alpha(2c) adrenergic knockout mice;
D O I
10.1152/ajpregu.00424.2007
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Sympathetic hyperactivity (SH) and renin angiotensin system (RAS) activation are commonly associated with heart failure (HF), even though the relative contribution of these factors to the cardiac derangement is less understood. The role of SH on RAS components and its consequences for the HF were investigated in mice lacking alpha(2A) and alpha(2C) adrenoceptor knockout (alpha(2A)/alpha(2C) ARKO) that present SH with evidence of HF by 7 mo of age. Cardiac and systemic RAS components and plasma norepinephrine (PN) levels were evaluated in male adult mice at 3 and 7 mo of age. In addition, cardiac morphometric analysis, collagen content, exercise tolerance, and hemodynamic assessments were made. At 3 mo, alpha(2A)/alpha(2C)ARKO mice showed no signs of HF, while displaying elevated PN, activation of local and systemic RAS components, and increased cardiomyocyte width (16%) compared with wild-type mice (WT). In contrast, at 7 mo, alpha(2A)/alpha(2C)ARKO mice presented clear signs of HF accompanied only by cardiac activation of angiotensinogen and ANG II levels and increased collagen content (twofold). Consistent with this local activation of RAS, 8 wk of ANG II AT(1) receptor blocker treatment restored cardiac structure and function comparable to the WT. Collectively, these data provide direct evidence that cardiac RAS activation plays a major role underlying the structural and functional abnormalities associated with a genetic SH-induced HF in mice.
引用
收藏
页码:R26 / R32
页数:7
相关论文
共 43 条
[1]   Internally quenched fluorogenic substrates for angiotensin I-converting enzyme [J].
Araujo, MC ;
Melo, RI ;
Del Nery, E ;
Alves, MFM ;
Juliano, MA ;
Casarini, DE ;
Juliano, T ;
Carmona, AK .
JOURNAL OF HYPERTENSION, 1999, 17 (05) :665-672
[2]   Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist -: A functional role for receptor-receptor interaction in vivo [J].
Barki-Harrington, L ;
Luttrell, LM ;
Rockman, HA .
CIRCULATION, 2003, 108 (13) :1611-1618
[3]   Neurohumoral activation in heart failure: the role of adrenergic receptors [J].
Brum, Patricia C. ;
Rolim, Natale P. L. ;
Bacurau, Aline V. N. ;
Medeiros, Alessandra .
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2006, 78 (03) :485-503
[4]   Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice [J].
Brum, PC ;
Kosek, J ;
Patterson, A ;
Bernstein, D ;
Kobilka, B .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 283 (05) :H1838-H1845
[5]   Differential effects of isoproterenol on the activity of angiotensin-converting enzyme in the rat heart and aorta [J].
Busatto, VCW ;
Cunha, V ;
Cicilini, MA ;
Mill, JG .
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1999, 32 (03) :355-360
[6]   Transforming growth factor β receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II [J].
Chen, K ;
Mehta, JL ;
Li, DY ;
Joseph, L ;
Joseph, J .
CIRCULATION RESEARCH, 2004, 95 (12) :1167-1173
[7]   Profibrotic effects of angiotensin II in the heart -: A matter of mediators [J].
Díez, J .
HYPERTENSION, 2004, 43 (06) :1164-1165
[8]   The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function [J].
Dostal, DE .
REGULATORY PEPTIDES, 2000, 91 (1-3) :1-11
[9]   The cardiac renin-angiotensin system - Conceptual, or a regulator of cardiac function? [J].
Dostal, DE ;
Baker, KM .
CIRCULATION RESEARCH, 1999, 85 (07) :643-650
[10]  
Dzau V J, 1988, Am J Med, V84, P22, DOI 10.1016/0002-9343(88)90201-X